SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced that it has entered into a supply agreement for its QuickVue® iFOB (immunochemical Fecal Occult Blood) test with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH). LabCorp’s determination to standardize on the QuickVue iFOB test followed LabCorp’s comprehensive clinical evaluations of various immunochemical test products. The QuickVue iFOB patient collection kits will be distributed to patients throughout LabCorp’s 1700 patient service centers and affiliated physician offices nationwide, and the QuickVue iFOB tests will be utilized at LabCorp’s 36 regional laboratories.
